^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification

Excerpt:
...- Small cell lung cancer harboring RICTOR amplification...
Trial ID:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR

Excerpt:
In parallel, cells with RICTOR copy number (CN) gain showed increased sensitivity to three mTOR inhibitors, AZD8055, AZD2014 and INK128 in cell growth assays, with AZD2014 demonstrating the best inhibition of downstream signaling.
DOI:
10.18632/oncotarget.13362